Skip to main content
Sanofi's drug for rare low platelet disorder approved by FDA
2/7/2019

Sanofi's Cablivi, or caplacizumab-yhdp, has been approved by the FDA for use in combination with plasma exchange and immunosuppression as a treatment for adult patients with acquired thrombotic thrombocytopenic purpura.

Full Story: